Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 4/20 | 0.51 |
| ▸ | NMUR2 | Q9GZQ4 | 5/20 | 0.50 |
| ▸ | NMUR1 | Q9HB89 | 4/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.48 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.46 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.44 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29601373 | 0.96 | MAPK8 (0.52) | CALCRLNMUR2NMUR1MAPK8MAPK9 | |
| SCHEMBL29506914 | 0.94 | MAPK8 (0.51) | CALCRLNMUR2NMUR1MAPK8MAPK9 | |
| SCHEMBL29506913 | 0.93 | MAPK8 (0.50) | CALCRLNMUR2NMUR1MAPK8MAPK9 | |
| SCHEMBL31049835 | 0.92 | MAPK8 (0.48) | CALCRLNMUR2NMUR1MAPK8MAPK9 | |
| SCHEMBL29506912 | 0.90 | MAPK8 (0.52) | CALCRLNMUR2NMUR1MAPK8MAPK9 | |
| SCHEMBL31049840 | 0.90 | MAPK8 (0.47) | CALCRLNMUR2NMUR1MAPK8MAPK9 | |
| SCHEMBL29634985 | 0.89 | CALCRL (0.57) | CALCRLNMUR2NMUR1KEAP1 | |
| SCHEMBL29506916 | 0.86 | APLNR (0.52) | CALCRLMAPK8MAPK9MAPK10CXCL8 | |
| SCHEMBL31490515 | 0.86 | MAPK8 (0.54) | CALCRLNMUR2NMUR1MAPK8MAPK9 | |
| SCHEMBL31490504 | 0.85 | MAPK8 (0.52) | CALCRLNMUR2NMUR1MAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260061086-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-05 | — | — | US | disclosed |
| US-12427210-B2 | Compounds comprising a fibroblast activation protein ligand and use thereof | 3B PHARMACEUTICALS GMBH (DE) | 2025-09-30 | — | — | US | disclosed |
| EP-4517326-A2 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2025-03-05 | — | — | EP | disclosed |
| EP-3997103-B9 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2025-02-26 | — | — | EP | disclosed |
| EP-3997103-B1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2024-11-20 | — | — | EP | disclosed |
| EP-4274835-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2023-11-15 | — | — | EP | disclosed |
| US-20230212549-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2023-07-06 | — | — | US | disclosed |
| US-20220315554-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2022-10-06 | — | — | US | disclosed |
| US-20220273831-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2022-09-01 | — | — | US | disclosed |
| WO-2022148843-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2022-07-14 | — | — | WO | disclosed |
| EP-3997104-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2022-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315554-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | FIBP, FN1, TPX2 | CALCRL 1223/4885NMUR2 1993/4885NMUR1 1377/4885 |
| US-20230212549-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | FIBP, FN1, TPX2 | CALCRL 1223/4885NMUR2 1993/4885NMUR1 1377/4885 |
| US-20260061086-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | FAP, FIBP, FGF23 | CALCRL 39/4885NMUR2 2992/4885NMUR1 2835/4885 |
| US-20220273831-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | FIBP, FGF2, FRS2 | CALCRL 532/4885NMUR2 1629/4885NMUR1 1427/4885 |
| US-12427210-B2 | Compounds comprising a fibroblast activation protein ligand and use thereof | FIBP, FGF2, FRS2 | CALCRL 532/4885NMUR2 1629/4885NMUR1 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.